Efficacy of Tramadol With Levobupivacaine for Modified Pectoral Nerve Block

September 9, 2020 updated by: Mansoura University

Efficacy of Adding Tramadol as Adjunctive Analgesic With Levobupivacaine in Modified Pectoral Nerve Block for Modified Radical Mastectomy Surgery

The aim of this study is to evaluate the addition of tramadol combined with levobupivacaine in the reduction of postoperative pain, postoperative opioid consumption after modified radical mastectomy surgery.

Study Overview

Detailed Description

Breast surgeries are usually associated with sever postoperative pain ,good perioperative analgesic technique after breast surgery is always questionable Thoracic epidural and paravertebral blocks became the gold standard techniques for pain relief, however they may be associated with complications such as spinal cord injury, total spinal anesthesia ,inadvertent intravascular injection and pneumothorax.

Pecs block is less invasive procedure involving ultrasound guided inter-fascial injections which has been suggested as potential alternative analgesic technique.

The block produces excellent analgesia and can be used as a rescue block in cases where the analgesia provided by the paravertebral or epidural was patchy or ineffective .

Different drugs, including opioids, non-steroidal anti-inflammatory drugs, ketamine, clonidine, and neostigmine, have been added to local anesthetics to improve the duration and quality of analgesia.Tramadol has also been used for pain management of patients.

The power of this clinical trial was prospectively calculated using the G Power analysis program. Using a priory power analysis with accuracy mode calculations with visual analogue score (VAS) as the primary variant and assuming type I error protection of 0.05 and an effect size convention of 0.9, a total sample size of 54 patients (27 patients in each group) produced a power of 0.90. To protect against drop out cases we added 6 cases to the total number (total of 60 cases)

Study Type

Interventional

Enrollment (Actual)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • DK
      • Mansoura, DK, Egypt, 050
        • Mansoura University, Mansoura Oncology Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • American Society of Anesthesiologists physical status I or II.
  • Patients scheduled for radical mastectomy surgery.

Exclusion Criteria:

  • Severe or uncompensated cardiovascular diseases
  • renal diseases
  • Hepatic diseases
  • Endocrinal diseases.
  • Pregnancy
  • Postpartum
  • Lactating females
  • Allergy to study medications.
  • Local skin infection
  • Bleeding disorder
  • Coagulation abnormality
  • Spine deformity
  • chest deformity
  • Psychiatric disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Levobupivacaine
Patients will be subjected for radical mastectomy surgery and pectoral nerve block with levobupivacaine
Ultrasound guided Pecs block will be performed using 20 ml of levobupivacaine
Active Comparator: Levobupivacaine and Tramadol
Patients will be subjected for radical mastectomy surgery and pectoral nerve block with levobupivacaine and tramadol
Ultrasound guided Pecs block will be performed using 20 ml of levobupivacaine in conjunction with tramadol

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Postoperative pain
Time Frame: For the first 24 hours after surgery
Postoperative pain will be assessed by utilizing visual analogue scale (VAS)
For the first 24 hours after surgery

Secondary Outcome Measures

Outcome Measure
Time Frame
Changes in heart rate
Time Frame: For one hour after surgery
For one hour after surgery
Changes in blood pressure
Time Frame: For one hour after surgery
For one hour after surgery
Changes in peripheral oxygen saturation
Time Frame: For one hour after surgery
For one hour after surgery
Changes in end-tidal carbon dioxide tension
Time Frame: For one hour after surgery
For one hour after surgery
Time for first analgesic request from extubation
Time Frame: for 24 hours after surgery
for 24 hours after surgery
Total analgesics received for 24 hrs after surgery
Time Frame: for 24 hours after surgery
for 24 hours after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Salwa MS Hayes, MD, assistant professor of Anesthesia and Surgical Intensive Care
  • Study Director: Reem A Sharkawy, MD, Lecture of Anesthesia and Surgical Intensive Care
  • Study Chair: Tamer EM Farahat, MD, Lecture of Anesthesia and Surgical Intensive Care

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2012

Primary Completion (Actual)

December 1, 2015

Study Completion (Actual)

January 1, 2016

Study Registration Dates

First Submitted

November 21, 2015

First Submitted That Met QC Criteria

December 5, 2015

First Posted (Estimate)

December 9, 2015

Study Record Updates

Last Update Posted (Actual)

September 11, 2020

Last Update Submitted That Met QC Criteria

September 9, 2020

Last Verified

September 1, 2020

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Cancer

Clinical Trials on Levobupivacaine

3
Subscribe